AMRX (Amneal Pharmaceuticals) ROCE %: 19.05% (As of Mar. 2026)

What is Amneal Pharmaceuticals ROCE %?

Amneal Pharmaceuticals AMRX -0.49% 63 ROCE % is 19.05% as of Mar. 2026. GuruFocus rates AMRX with a GF Score™ of 63/100 and a GF Value™ of $7.57 (Significantly Overvalued). The stock has 6 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Amneal Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was 19.05%.

Amneal Pharmaceuticals (NAS:AMRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Amneal Pharmaceuticals ROCE % Related Terms

Amneal Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Amneal Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amneal Pharmaceuticals ROCE % Chart

Amneal Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

ROCE %

Get a 7-Day Free Trial

5.09

-2.85

6.01

8.15

14.72

Amneal Pharmaceuticals Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															16.21	20.29	9.12	16.11	19.05

63GF Score

Amneal Pharmaceuticals Inc AMRX

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Amneal Pharmaceuticals ROCE % Calculation

Amneal Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2025 )		(A: Dec. 2024 )		(A: Dec. 2025 )
	=	380.3	/	( ( (3501.445 - 1129.771)	+	(3678.28 - 881.633) )	/ 2 )
	=	380.3	/	( (2371.674	+	2796.647)	/ 2 )
	=	380.3	/	2584.1605
	=	14.72 %

Amneal Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	534.148	/	( ( (3678.28 - 881.633)	+	(3540.218 - 728.049) )	/ 2 )
	=	534.148	/	( ( 2796.647	+	2812.169 )	/ 2 )
	=	534.148	/	2804.408
	=	19.05 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 19.05% mean?

Amneal Pharmaceuticals (AMRX) has a ROCE % of 19.05% as of Mar. 2026.

Is Amneal Pharmaceuticals' ROCE % too high?

Amneal Pharmaceuticals' current ROCE % is 19.05%. The Drug Manufacturers industry median ROCE % is 7.00. Amneal Pharmaceuticals' value of 19.05% is 172.3% above this industry median. Overall, Amneal Pharmaceuticals has a GF Score™ of 63/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Amneal Pharmaceuticals' ROCE % compare to INDV and KNSA?

Amneal Pharmaceuticals' ROCE % of 19.05% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.00. Amneal Pharmaceuticals' value of 19.05% is 172.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.00, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Amneal Pharmaceuticals's current ROCE % of 19.05% is 172.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Amneal Pharmaceuticals's current ROCE % is 19.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Amneal Pharmaceuticals stock overvalued right now?

Based on GuruFocus' analysis, Amneal Pharmaceuticals (AMRX) is currently considered Significantly Overvalued. The stock's GF Value™ is $7.57, compared to a current price of $17.24 — trading 127.7% above its estimated fair value. The current ROCE % is 19.05% and 172.3% above the Drug Manufacturers industry median of 7.00. Amneal Pharmaceuticals' overall GF Score™ is 63/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Amneal Pharmaceuticals (AMRX), the current ROCE % is 19.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amneal Pharmaceuticals (AMRX) Overvalued in 2026?

Based on GuruFocus' analysis, Amneal Pharmaceuticals stock appears to be overvalued. The current stock price of $17.24 is trading 127.7% above its estimated GF Value™ of $7.57. GuruFocus considers Amneal Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for AMRX:

ROCE %: 19.05%
GF Value™: $7.57 vs. price of $17.24 (127.7% above fair value)
GF Score™: 63/100 with 6 warning signs
Industry Position: 172.3% above the Drug Manufacturers median

No single metric tells the full story. See the AMRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Amneal Pharmaceuticals Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies INDV KNSA LQDA SUPN HIMS BCRX PBH LNTH ANIP AMLX XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges 2DT:Germany

Address 400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807

Website https://www.amneal.com

Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

63GF Score

Get the complete analysis for AMRX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$17.24

Price

$7.57

GF Value

View AMRX Analysis

See ROCE % data for all stocks →